Active Ingredient History
Drospirenone (INN, USAN), also known as 1,2-dihydrospirorenone, is a steroidal progestin of the spirolactone group. Drospirenone binds strongly to the progesterone receptor (PR) and mineralocorticoid receptor (MR), with lower affinity, to the androgen receptor (AR), and very low affinity for the glucocorticoid receptor (GR). Drospirenone is an ingredient in some birth control pills and hormone replacement therapy. In combination with ethinylestradiol it is used as contraception, and for women who want contraception it is also approved by the U.S. Food and Drug Administration (FDA) to treat vasomotor symptoms due to menopause.It is sold as a combined oral contraceptive under the brand names Yasmin (US, EU, Latin America), Jasmine (France), Yarina (Russia) in a dosage containing drospirenone 3 mg/ethinylestradiol 30 µg. In the United States, Bayer Schering released a pill based on Yasmin with the B vitamin folate (B9), which is marketed under the names Safyral and Beyaz. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Contraception (approved 2001)
Adenomyosis (Early Phase 1)
Alveolar Bone Loss (Phase 4)
Binge-Eating Disorder (Phase 2)
Biological Availability (Phase 1)
Bipolar Disorder (Phase 2)
Blood Pressure (Phase 4)
Body Weight Changes (Phase 4)
Bone Diseases (Phase 4)
Bulimia (Phase 2)
Bulimia Nervosa (Phase 2)
Cardiovascular Diseases (Phase 4)
Chlamydia Infections (Phase 4)
Climacteric (Phase 4)
Contraception (Phase 4)
Contraceptive Agents (Phase 4)
Contraceptives, Oral (Phase 3)
Depression (Phase 2)
Dysmenorrhea (Phase 4)
Dyspareunia (Phase 4)
Endometriosis (Phase 4)
Feeding and Eating Disorders (Phase 2)
Growth and Development (Phase 1)
Guillain-Barre Syndrome (Phase 3)
Healthy Volunteers (Phase 4)
Hemostasis (Phase 1/Phase 2)
Hidradenitis Suppurativa (Phase 2)
HIV (Phase 1)
HIV Infections (Phase 4)
Hormone Replacement Therapy (Phase 4)
Hot Flashes (Phase 3)
Hyperandrogenism (Phase 4)
Hypertension (Phase 3)
Joint Diseases (Phase 4)
Menstruation Disturbances (Phase 4)
Metabolism (Phase 1/Phase 2)
Neisseriaceae Infections (Phase 4)
Neonatal Sepsis (Phase 3)
Neural Tube Defects (Phase 3)
Ovarian Follicle (Phase 1)
Ovulation Inhibition (Phase 3)
Pelvic Pain (Phase 4)
Polycystic Ovary Syndrome (Phase 4)
Postmenopause (Phase 4)
Pregnancy Complications (Phase 3)
Prehypertension (Phase 2)
Premenstrual Dysphoric Disorder (Phase 4)
Premenstrual Syndrome (Phase 4)
Primary Ovarian Insufficiency (Phase 3)
Safety (Phase 3)
Vaginal Diseases (Phase 3)
Vasomotor System (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue